161374-55-6
161374-55-6 结构式
基本信息
Heptamidine dimethanesulfote
Heptamidine dimethanesulfonate
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-16918A | SBi4211 dimethanesulfonate Heptamidine dimethanesulfonate | 161374-55-6 | 5mg | 2100元 |
| 2024/04/30 | S3389 | SBi4211 dimethanesulfonate Heptamidine?Dimethanesulfonate | 161374-55-6 | 5mg | 2366.91元 |
| 2024/04/30 | HY-16918A | SBi4211 dimethanesulfonate Heptamidine dimethanesulfonate | 161374-55-6 | 10mM * 1mLin DMSO | 2590元 |
常见问题列表
Kd: 6.9 μM (calcium-binding protein S100B)
Heptamidine is a Pentamidine-S100B complex, two molecules of pentamidine bind per monomer of S100B, which performs to be an inhibitor for S100B.Heptamidine (20 μM) does not decrease CUG levels significantly when compares to Propamidine and Pentamidine, and exhibits cytotoxic at concentrations above 17.5 μM in HeLa cells expressing 960 CUG repeats.Heptamidine rescues mis-splicing of minigene reporters in a HeLa cell DM1 model with an EC 50 value of 15 μM.
Heptamidine (intraperitoneal injection; 20 or 30 mg/kg; 7 days) causes a dose-dependent reduction of exon 7a inclusion in HSA LR mice, returning to wild type levels (6±1%) when at 20 mg/kg dose, the myotonia is reduced from grade 3 to grade 1 (occasional myotonic discharge) or grade 0 at both 20 or 30 mg/kg.
| Animal Model: | Homozygous HSALR transgenic mice in line 20b (FVB inbred background) with a Myotonic dystrophy (DM) mouse model |
| Dosage: | 20 or 30 mg/kg |
| Administration: | Intraperitoneal injection; 7 days; once daily |
| Result: | Reversed splicing defects and rescues myotonia in a DM mouse model. |